Company: IPSC
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001104659-25-037419
Chunk: 14

Company: Century Therapeutics, Inc.
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 14
---
 and financial reporting and knowledge of the biopharmaceutical industry.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |   |   |                                                                           |   |   |                                                                | ​ | ​ |

| ​ | ​ | CARLO RIZZUTO, PH.D.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |   |   |                                                                                  | ​ | ​ | Key Skills:Investing and Capital Raising, Industry Knowledge and Experience | ​ | ​ |
| ​ | ​ | Age: 54Director Since: 2018                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | ​ | ​ | Committee Memberships: Compensation (Chair), Nominating and Corporate Governance | ​ | ​ | Other Public Directorships: N/A                                             | ​ | ​ |
| ​ | ​ | Dr. Rizzutohas served as a member of our Board since March 2018. From April 2018 until August 2018, Dr. Rizzuto was our President, Secretary and Treasurer. Dr. Rizzuto joined Versant Ventures in November 2012 where he currently serves as Managing Director, and has served in a variety of roles including operating principal, venture partner and partner. Prior to joining Versant Ventures, Dr. Rizzuto worked at Novartis AG, where he was a global program team director from 2010 until 2012. Dr. Rizzuto previously served as Chief Business Officer of Anokion SA, a biopharmaceutical company, from January 2014 to January 2017. Dr. Rizzuto previously served on the board of directors of Graphite Bio from March 2020 until March 2024, and Pandion Therapeutics, Inc. from January 2018 until March 2021. Dr. Rizzuto received a Ph.D. in virology from Harvard University and a B.A. in biology from the University of Virginia. |   |   |                                                                                  |   |   |                                                                             | ​ | ​ |
| ​ | ​ | Skills & Qualifications: We believe that Dr. Rizzuto is qualified to serve on our Board due to his knowledge and experience as an investor in the life sciences industry.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |   |   |                                                                                  |   |   |                                                                             | ​ | ​ |

Notice of Annual Meeting of Stockholders and 2025 Proxy Statement | 6

TABLE OF CONTENTS

| ​ | BOARD OF DIRECTORS | ​ |

CONTINUING DIRECTORS CLASS II DIRECTORS — TERMS EXPIRING